|
|
5203 Bristol Industrial Way
Buford, GA 30518 USA
phone:770-271-0233
fax:770-831-5294
|
|
| Symbol |
TGX |
| Exchange |
NYSE |
| Founded |
1981 |
| Employees |
336 |
|
|
| www.theragenics.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Implantable therapeutic delivery systems for prostate cancer treatment, and surgical devices for wound closure and vascular access |
|
| Management |
| M. Christine Jacobs, Chief Executive Officer; Michael Lang, President, Galt Medical; Patrick J. Ferguson, President, CP Medical; R. Michael O. Bannon, Ph.D., Executive Vice President Organizational Development; Bruce W. Smith, Executive Vice President Strategy and Business Development; Frank J. Tarallo, Chief Financial Officer and Treasurer |
| |
|
|
|
|
|
|
|
| Keywords |
| Brachytherapy, seeding, wound closure, vascular access |
|
|
|
| Description |
|
Theragenics Corporation operates two business segments: its brachytherapy seed business and its surgical products business. The brachytherapy business manufactures and markets its premier product, TheraSeed�, a palladium-103 based device, I-Seed, an iodine-125 based device, and related products and services. Physicians implant these 'seeds' during a one-time, minimally invasive procedure, usually performed on an outpatient basis, primarily to treat patients with localized prostate cancer. Its surgical products business manufactures and distributes wound closure, vascular, and interventional products. |
|
| Products / Services |
Theragenics' brachytherapy seed segment offers TheraSeed, a rice-sized palladium-103 device used to treat solid localized tumors, such as prostate cancer. This segment also manufactures and distributes I-Seed, an iodine-125 based medical device for the treatment of prostate cancer and related brachytherapy products and services. Its surgical products segment offers Wound Closure products through its subsidiary CP Medical, and Vascular Access products through its subsidiary Galt Medical.
The CP Medical Wound Closure and Medical Products segment manufactures and supplies sutures, cardiac pacing cables, brachytherapy needles/spacers/sleeves and other related medical products for wound closure, cardiac pacing, and the general, dental, cosmetic and veterinary surgery markets.
|
|
| Technology / Differentiation |
| TheraSeed devices are implanted throughout the prostate gland in a minimally invasive surgical technique, with transrectal ultrasound guidance. The radiation emitted by the seeds is contained within the immediate prostate area for the purpose of killing the tumor while attempting to spare surrounding organs of significant radiation exposure. The device is best suited for solid localized tumors. |
|
| Market / Customers |
The company sells its products to the oncology, brachytherapy, interventional cardiology, interventional radiology, wound closure, general surgery, dental, cosmetic and veterinary surgery markets. Doctors have used TheraSeed devices to treat over 130,000 men for prostate cancer.
|
|
| Competitors / Substitutes / Alternatives |
Theragenics main competitors in brachytherapy are North American Scientific, Best Medical, Core Oncology, and IsoRay Medical. Its wound closure and vascular access divisions have large companies such as divisions of Tyco and J & J who are players in the same market, but Theragenics Galt Medical and CP Medical, the subsidiaries which make up the surgical products business, both concentrate on niche markets within their larger markets.
|
|
| Status |
| In February 2008, Theragenics announced consolidated financial results for the fourth quarter and year ended December 31, 2007. Consolidated revenue for the quarter was $15.2 million compared to $14.8 million in the fourth quarter of 2006, an increase of 3%. For the year, consolidated revenue was $62.2 million, the highest annual revenue in the Company's history, compared to $54.1 million in 2006, an increase of 15%. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members